8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
Apr 30, 2026·SEC
Material company update
Mar 30, 2026·SEC
Lexeo Therapeutics, Inc. Common Stock(LXEO)Earnings, Financials & Key Ratios
LXEO•NASDAQ
Price updated Jun 19, 2026
AboutLexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.Show more
- Revenue$0
- EBITDA-$107M-3.3%
- Net Income-$100M-1.7%
- EPS (Diluted)-1.86+39.8%
- ROE-55%+35.6%
LXEO Key Insights
Lexeo Therapeutics, Inc. Common Stock (LXEO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 1.1x book value
✗Weaknesses
- ✗Profits declining 80.9% over 5 years
- ✗Weak momentum: RS Rating 12 (bottom 12%)
- ✗Shares diluted 68.8% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when LXEO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
LXEO Price & Volume
Lexeo Therapeutics, Inc. Common Stock (LXEO) stock price & volume — 10-year historical chart
Loading chart...
LXEO Growth Metrics
Lexeo Therapeutics, Inc. Common Stock (LXEO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM19.95%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM56.06%
Return on Capital
10 Years-57.95%
5 Years-66.34%
3 Years-70.21%
Last Year-58.12%
LXEO Recent Earnings
Lexeo Therapeutics, Inc. Common Stock (LXEO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (55%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.25+13.8%
$0.29
Rev
—
—
Q2 2026
Mar 30, 2026Metric
Actual
Est
EPS
$0.27+15.6%
$0.32
Rev
—
—
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.33+31.3%
$0.48
Rev
—
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.60+6.3%
$0.64
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.25vs $0.29+13.8% | — |
| Q2 2026 | Mar 30, 2026 | $0.27vs $0.32+15.6% | — |
| Q4 2025 | Nov 5, 2025 | $0.33vs $0.48+31.3% | — |
| Q3 2025 | Aug 14, 2025 | $0.60vs $0.64+6.3% | — |
Based on last 12 quarters of dataView full earnings history →
LXEO Peer Comparison
Lexeo Therapeutics, Inc. Common Stock (LXEO) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCKT | 365.8M | 3.35 | -1.67 | -70.79% | 0.09 | |||
 KRYS | 10.26B | 348.06 | 50.89 | 33.94% | 53.92% | 19.25% | 0.01 | |
 SGMO | 74.57M | 0.18 | -0.41 | -31.57% | -356.89% | -28.92% | ||
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% | ||
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 ARWR | 11.52B | 81.82 | -6706.56 | 232.58% | -48.38% | -55.09% | 0.73 |
Compare LXEO vs Peers
Lexeo Therapeutics, Inc. Common Stock (LXEO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LXEO Income Statement
Lexeo Therapeutics, Inc. Common Stock (LXEO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Sales/Revenue | 518.48K | 1.66M | 654K | 0 | 0 | 0 | 0 |
Revenue Growth % | - | 219.59% | -60.53% | -100% | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 546K |
COGS % of Revenue | - | - | - | - | - | - | - |
Gross Profit | 518.48K▲ 0% | 1.66M▲ 219.6% | 654K▼ 60.5% | 0▼ 100.0% | 0▲ 0% | 0▲ 0% | -546K▲ 0% |
Gross Margin % | 100% | 100% | 100% | - | - | - | - |
Gross Profit Growth % | - | 219.59% | -60.53% | -100% | - | - | - |
Operating Expenses | 5.11M | 52.29M | 61.16M | 68.51M | 105.77M | 109.26M | 97.24M |
OpEx % of Revenue | 984.86% | 3155.94% | 9352.14% | - | - | - | - |
Selling, General & Admin | 787.5K | 7.17M | 12M | 15.38M | 31.68M | 45.46M | 35.46M |
SG&A % of Revenue | 151.89% | 432.89% | 1835.02% | - | - | - | - |
Research & Development | 4.32M | 45.12M | 49.16M | 53.13M | 74.09M | 63.8M | 62.33M |
R&D % of Revenue | 832.97% | 2723.05% | 7517.13% | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | -546K |
Operating Income | -4.59M▲ 0% | -50.64M▼ 1003.7% | -60.51M▼ 19.5% | -68.51M▼ 13.2% | -105.77M▼ 54.4% | -109.26M▼ 3.3% | -97.78M▲ 0% |
Operating Margin % | -884.86% | -3055.94% | -9252.14% | - | - | - | - |
Operating Income Growth % | - | -1003.73% | -19.5% | -13.23% | -54.37% | -3.3% | - |
EBITDA | -4.59M | -50.62M | -59.36M | -66.67M | -103.76M | -107.18M | -95.66M |
EBITDA Margin % | -884.86% | -3055.16% | -9077.06% | - | - | - | - |
EBITDA Growth % | - | -1003.45% | -17.26% | -12.31% | -55.64% | -3.29% | 16.27% |
D&A (Non-Cash Add-back) | 0 | 13K | 1.15M | 1.84M | 2M | 2.08M | 2.12M |
EBIT | -4.59M | -50.62M | -59.19M | -66.19M | -98.2M | -99.75M | -89.47M |
Net Interest Income | -147.15K | 15K | 1.23M | 2.66M | 7.44M | 5.92M | 6.91M |
Interest Income | 0 | 15K | 1.32M | 2.87M | 7.56M | 6.13M | 7.09M |
Interest Expense | 147.15K | 0 | 91K | 205K | 114K | 206K | 183K |
Other Income/Expense | -565K | 15K | 1.23M | 2.12M | 7.43M | 9.3M | 10.28M |
Pretax Income | -5.15M▲ 0% | -50.62M▼ 882.4% | -59.28M▼ 17.1% | -66.39M▼ 12.0% | -98.33M▼ 48.1% | -99.96M▼ 1.7% | -87.5M▲ 0% |
Pretax Margin % | -993.83% | -3055.04% | -9063.76% | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -5.15M▲ 0% | -50.62M▼ 882.4% | -59.28M▼ 17.1% | -66.39M▼ 12.0% | -98.33M▼ 48.1% | -99.96M▼ 1.7% | -87.5M▲ 0% |
Net Margin % | -993.83% | -3055.04% | -9063.76% | - | - | - | - |
Net Income Growth % | - | -882.42% | -17.1% | -12.01% | -48.11% | -1.66% | 19.95% |
Net Income (Continuing) | -5.15M | -50.62M | -59.28M | -66.39M | -98.33M | -99.96M | -87.5M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.20▲ 0% | -2.01▼ 905.0% | -2.40▼ 19.4% | -2.49▼ 3.8% | -3.09▼ 24.1% | -1.86▲ 39.8% | -1.08▲ 0% |
EPS Growth % | - | -905% | -19.4% | -3.75% | -24.1% | 39.81% | 56.06% |
EPS (Basic) | -0.20 | -2.01 | -2.36 | -2.49 | -3.09 | -1.86 | - |
Diluted Shares Outstanding | 25.17M | 25.17M | 25.17M | 26.65M | 31.79M | 53.65M | 81.18M |
Basic Shares Outstanding | 25.17M | 25.17M | 25.17M | 26.65M | 31.79M | 53.65M | 81.18M |
Dividend Payout Ratio | - | - | - | - | - | - | - |
LXEO Balance Sheet
Lexeo Therapeutics, Inc. Common Stock (LXEO) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Total Current Assets | 29.41M | 136.68M | 80.05M | 124.29M | 126.12M | 188.39M | 200.86M |
Cash & Short-Term Investments | 29.37M | 135.86M | 77.33M | 121.47M | 121.52M | 181.77M | 71.77M |
Cash Only | 29.37M | 135.86M | 77.33M | 121.47M | 35.01M | 63M | 71.77M |
Short-Term Investments | 0 | 0 | 0 | 0 | 86.5M | 118.77M | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - |
Other Current Assets | 33.57K | 696K | 371K | 3K | 4.6M | 6.63M | 129.09M |
Total Non-Current Assets | 2.5K | 176K | 21.26M | 15.51M | 20.82M | 80.3M | 49.49M |
Property, Plant & Equipment | 0 | 174K | 13.78M | 12.26M | 10.56M | 8.86M | 8.35M |
Fixed Asset Turnover | - | 9.52x | 0.05x | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 7.01M | 71.44M | 128.95M |
Other Non-Current Assets | 2.5K | 2K | 7.49M | 3.25M | 3.25M | 0 | 6.64M |
Total Assets | 29.41M▲ 0% | 136.86M▲ 365.4% | 97.08M▼ 29.1% | 139.81M▲ 44.0% | 146.94M▲ 5.1% | 268.69M▲ 82.9% | 250.36M▲ 0% |
Asset Turnover | 0.02x | 0.01x | 0.01x | - | - | - | 0.00x |
Asset Growth % | - | 365.36% | -29.07% | 44.02% | 5.1% | 82.85% | 156.47% |
Total Current Liabilities | 697.72K | 7.45M | 14.35M | 17.24M | 22.85M | 16.81M | 14.19M |
Accounts Payable | 44.32K | 3.06M | 2.68M | 3.79M | 6.42M | 4.86M | 3.33M |
Days Payables Outstanding | - | - | - | - | - | - | 5.49K |
Short-Term Debt | 0 | 0 | 0 | 0 | 2.67M | 0 | 2.69M |
Deferred Revenue (Current) | 140.38K | 46K | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1.03K | 961K | 2.15M | 3.36M | 4.66M | 9.28M | 8.16M |
Current Ratio | 42.15x | 18.35x | 5.58x | 7.21x | 5.52x | 11.21x | 14.16x |
Quick Ratio | 42.15x | 18.35x | 5.58x | 7.21x | 5.52x | 11.21x | 14.16x |
Cash Conversion Cycle | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 34.25M | 185.01M | 195.68M | 9.03M | 7.25M | 5.21M | 4.67M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 4.67M |
Capital Lease Obligations | 0 | 0 | 10.65M | 9.03M | 7.25M | 5.21M | 11.47M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 34.25M | 185.01M | 185.03M | 0 | 0 | 0 | 0 |
Total Liabilities | 34.95M | 192.46M | 210.03M | 26.27M | 30.1M | 22.02M | 18.86M |
Total Debt | 0 | 0 | 13.48M | 11.64M | 9.92M | 7.89M | 7.37M |
Net Debt | -29.37M | -135.86M | -63.85M | -109.83M | -25.09M | -55.11M | -64.4M |
Debt / Equity | - | - | - | 0.10x | 0.08x | 0.03x | 0.03x |
Debt / EBITDA | - | - | - | - | - | - | -0.08x |
Net Debt / EBITDA | - | - | - | - | - | - | 0.67x |
Interest Coverage | -31.18x | - | -650.40x | -322.87x | -861.37x | -484.25x | -488.92x |
Total Equity | -5.54M▲ 0% | -55.6M▼ 904.3% | -112.95M▼ 103.1% | 113.53M▲ 200.5% | 116.84M▲ 2.9% | 246.67M▲ 111.1% | 231.5M▲ 0% |
Equity Growth % | - | -904.29% | -103.15% | 200.51% | 2.91% | 111.11% | 244.36% |
Book Value per Share | -0.22 | -2.21 | -4.49 | 4.26 | 3.68 | 4.60 | 2.85 |
Total Shareholders' Equity | -5.54M | -55.6M | -112.95M | 113.53M | 116.84M | 246.67M | 231.5M |
Common Stock | 1.6K | 1.68K | 0 | 3K | 3K | 7K | 7K |
Retained Earnings | -5.55M | -56.17M | -115.45M | -181.84M | -280.17M | -380.13M | -400.33M |
Treasury Stock | 0 | 0 | 0 | 0 | -17K | -17K | 0 |
Accumulated OCI | 0 | -185.01M | -185.03M | 0 | -103K | 188K | -142K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LXEO Cash Flow Statement
Lexeo Therapeutics, Inc. Common Stock (LXEO) cash flow — operating, investing & free cash flow history
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Cash from Operations | -3.13M | -44.18M | -54.56M | -59.5M | -81.15M | -98.56M | -97.99M |
Operating CF Margin % | -604.35% | -2666.39% | -8342.51% | - | - | - | - |
Operating CF Growth % | - | -1310.04% | -23.49% | -9.05% | -36.4% | -21.45% | -69.26% |
Net Income | -5.15M | -50.62M | -59.28M | -66.39M | -98.33M | -99.96M | -87.5M |
Depreciation & Amortization | 0 | 13K | 1.15M | 1.84M | 2M | 379K | 1.99M |
Stock-Based Compensation | 0 | 386K | 1.78M | 3.04M | 12.47M | 12.13M | 11.19M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 1.87M | 0 | 0 | 530K | -23K | -1.6M | -3.22M |
Working Capital Changes | 150.15K | 6.04M | 1.79M | 1.48M | 2.73M | -9.52M | -20.45M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 44.32K | 3.02M | -426K | -180K | 2.38M | -1.56M | -8.3M |
Cash from Investing | 0 | -188K | -901K | -165K | -94.08M | -90.25M | -78.39M |
Capital Expenditures | 0 | -188K | -672K | -115K | -481K | -397K | -432K |
CapEx % of Revenue | - | 11.35% | 102.75% | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | -229K | -50K | 0 | 17K | 17K |
Cash from Financing | 32.38M | 150.86M | 189K | 103.79M | 88.78M | 216.79M | 219.24M |
Debt Issued (Net) | 2.6M | 0 | -163K | 3.58M | -410K | -533K | -495K |
Equity Issued (Net) | 30M | 151.06M | 20K | 100.25M | 88.69M | 217.33M | 226.61M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | -17K | 0 | 0 |
Other Financing | -223.59K | -203K | 332K | -35K | 491K | 0 | -6.88M |
Net Change in Cash | 29.25M▲ 0% | 106.49M▲ 264.1% | -55.27M▼ 151.9% | 44.13M▲ 179.8% | -86.45M▼ 295.9% | 27.98M▲ 132.4% | 42.85M▲ 0% |
Free Cash Flow | -3.13M▲ 0% | -44.37M▼ 1316.0% | -55.46M▼ 25.0% | -59.66M▼ 7.6% | -81.63M▼ 36.8% | -98.96M▼ 21.2% | -98.42M▲ 0% |
FCF Margin % | -604.35% | -2677.73% | -8480.28% | - | - | - | - |
FCF Growth % | - | -1316.04% | -25% | -7.57% | -36.83% | -21.22% | -11.48% |
FCF per Share | -0.12 | -1.76 | -2.20 | -2.24 | -2.57 | -1.84 | -1.21 |
FCF Conversion (FCF/Net Income) | 0.61x | 0.87x | 0.92x | 0.90x | 0.83x | 0.99x | 1.12x |
Interest Paid | 0 | 0 | 77K | 176K | 127K | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LXEO Key Ratios
Lexeo Therapeutics, Inc. Common Stock (LXEO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | -22855.08% | -85.37% | -55% | -47.48% |
Return on Invested Capital (ROIC) | - | - | - | -166.2% | -57.85% | -52.52% |
Gross Margin | 100% | 100% | - | - | - | - |
Net Margin | -3055.04% | -9063.76% | - | - | - | - |
Debt / Equity | - | - | 0.10x | 0.08x | 0.03x | 0.03x |
Interest Coverage | - | -650.40x | -322.87x | -861.37x | -484.25x | -488.92x |
FCF Conversion | 0.87x | 0.92x | 0.90x | 0.83x | 0.99x | 1.12x |
Revenue Growth | 219.59% | -60.53% | -100% | - | - | - |
Related:LXEO Dividend History·LXEO Revenue History·LXEO Price History·LXEO P/E History·LXEO Financial Ratios·LXEO Institutional Holders
LXEO SEC Filings & Documents
Lexeo Therapeutics, Inc. Common Stock (LXEO) SEC filings — annual & quarterly reports (10-K, 10-Q)
LXEO Frequently Asked Questions
Lexeo Therapeutics, Inc. Common Stock (LXEO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Lexeo Therapeutics, Inc. Common Stock (LXEO) grew revenue by 0.0% over the past year. Growth has been modest.
Lexeo Therapeutics, Inc. Common Stock (LXEO) reported a net loss of $87.5M for fiscal year 2025.
Dividend & Returns
Lexeo Therapeutics, Inc. Common Stock (LXEO) has a return on equity (ROE) of -55.0%. Negative ROE indicates the company is unprofitable.
Lexeo Therapeutics, Inc. Common Stock (LXEO) had negative free cash flow of $98.4M in fiscal year 2025, likely due to heavy capital investments.